首页> 外文期刊>Therapeutic Drug Monitoring >Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy
【24h】

Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy

机译:UGT1A4和UGT2B7多态性与治疗抑制障碍患者乳三甲术治疗抑郁症接受乳草嗪的关系与UGT2B7多态性及稳态血浆浓度

获取原文
获取原文并翻译 | 示例
       

摘要

Background: In a previous study, the authors had shown that in treatment-resistant depressive disorder, an early therapeutic response to lamotrigine augmentation therapy is dependent on its plasma concentrations. Lamotrigine is mainly metabolized by UGT1A4 and UGT2B7, and polymorphisms of said UGTs that affect enzyme activities have been reported. This study investigated the effect of these polymorphisms on the steady-state plasma concentrations (Css) of lamotrigine in patients with treatment-resistant depressive disorder receiving lamotrigine as augmentation therapy.
机译:背景:在先前的研究中,作者表明,在耐治疗抑郁症中,对乳甲增强治疗的早期治疗反应依赖于其血浆浓度。 晶甲酮主要由UGT1A4和UGT2B7代谢,并且已经报道了影响酶活性的UGT的多态性。 本研究研究了这些多态性对抗治疗抑郁症患者的延长症稳态血浆浓度(CSS)的效果,接受乳草嗪作为增强治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号